(4) Inventory

After approval of Vascepa on July 26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories consist of the following (in thousands):


	December 31, 2014		December 31, 2013
Raw materials, current	$	5,225	$	4,246
Work in process		4,757		11,310
Finished goods		3,751		5,026
Finished goods inventory held by others		—		627

Total inventory, current		13,733		21,209

Raw materials, long-term		—		5,482

Total inventory	$	13,733	$	26,691

During the years ended December 31, 2014 and 2013, the Company wrote off zero and $1.8 million, respectively, of inventories deemed to be unrecoverable. In addition, as of December 31, 2014 and 2013, zero and $5.5 million, respectively, of raw material inventory was reclassified to long-term inventory, as it was not anticipated to be sold within the next twelve months based on current estimates.